Skip to main content

Table 1 The characteristics of 96 light chain multiple myeloma patients

From: Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study

Characteristics

With Velcade group(n = 66)

Without Velcade group(n = 30)

Total

P value

Age(years)

59(28–86)

58(43–77)

58(28–86)

>0.05

Sex(male/female)

34/29

17/16

51/45

>0.05

Albumin(g/L)

33.7(24.1-43.2)

32.1(17–42.4)

33.2(17–43.2)

>0.05

Leucocyte(X109/L)

5.4(1.0-11.7)

4.4(1.5-8.3)

5.1(1.0-11.7)

>0.05

Hemoglobin(g/L)

95.3(43–139)

99.3(51–140)

96.5(43–140)

>0.05

Platelet(X109/L)

189(33–389)

180(34–513)

186(33–513)

>0.05

C-reactive protein(mg/L)

12.76(0.62-60)

16.71(5.0-80)

13.89(0.62-80)

>0.05

Sedimentation(mm/h)

52(1.0-170)

53(2–140)

52(1–170)

>0.05

B2-microglobulin(mg/L)

7.51(1.06-38.15)

9.01(0.89-41.5)

7.96(0.89-41.5)

>0.05

Bone marrow plasmacytosis(%)

34.7(0.5-84)

40.2(3.5-95)

36.4(0.5-95)

>0.05

Lactate dehydrogenase(U/L)

179.5(91–849)

179.4(112–256)

179.5(91–849)

>0.05

Uric acid(umol/L)

346(130–590)

344(128–517)

345(128–590)

>0.05

Serum creatinine(umol/L)

177.3 (21.7-724.2)

108.5(31.27-507)

157.4(21.7-724.2)

>0.05

Light chain(g/24 hour)

23.9(1.0-128.8)

23.4(1.2-89.0)

23.8(1.2-128.8)

>0.05